- |||||||||| LidoPain (lidocaine) / Immune Pharma
Clinical, Journal: Is burning mouth syndrome a neuropathic pain condition? (Pubmed Central) - Apr 3, 2019 The central type does not respond to local treatments and associates often with psychiatric comorbidity (depression or anxiety), whereas the peripheral type responds to peripheral lidocaine blocks and topical clonazepam. Burning mouth syndrome is most prevalent in postmenopausal women, having led to a hypothesis that BMS is triggered as a consequence of nervous system damage caused by neurotoxic factors affecting especially vulnerable small fibers and basal ganglia in a setting of decrease in neuroprotective gonadal hormones and increase in stress hormone levels, typical for menopause.
- |||||||||| LidoPain (lidocaine) / Immune Pharma
Preclinical, Journal: Menthol reduces phototoxicity pain in a mouse model of photodynamic therapy. (Pubmed Central) - Mar 23, 2019 ...Inhibition of fatty acid amide hydrolase, selective antagonism of TRPV1 or the application of lidocaine or its quaternary derivative QX-314, reduced AP frequency, whereas antagonism of TRPA1 had no effect...Menthol inhibited phototoxicity-evoked APs and reduced pain behavior when applied topically to mice. These findings suggest that menthol might provide pain relief in patients experiencing PpIX-phototoxicity pain caused by photodynamic therapy or erythropoietic protoporphyria.
|